Loading...
Please wait, while we are loading the content...
Similar Documents
Transforming growth factor $β_{1}$genotype and change in left ventricular mass during antihypertensive treatment-results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (Silvhia)
| Content Provider | Scilit |
|---|---|
| Author | Hallberg, Pär Lind, Lars Billberger, Katarina Michaelsson, Karl Karlsson, Julia Kurland, Lisa Kahan, Thomas Malmqvist, Karin Öhman, K. Peter Nyström, Fredrik Liljedahl, Ulrika Syvänen, Ann-Christine Melhus, Håkan |
| Copyright Year | 2004 |
| Description | Journal: Clinical Cardiology Background: Angiotensin II, via the angiotensin II type 1 (AT1) receptor, may mediate myocardial fibrosis and myocyte hypertrophy seen in hypertensive left ventricular (LV) hypertrophy through production of transforming growth factor $β_{1}(TGF‐β_{1}$); AT1‐receptor antagonists reverse these changes. The $TGF‐(β_{1}$ G + 915C polymorphism is associated with in‐terindividual variation in TGF‐ $β_{1}$ production. No study has yet determined the impact of this polymorphism on the response to antihypertensive treatment. Hypothesis: We aimed to determine whether the TGF‐ $β_{1}$ G + 915C polymorphism was related to change in LV mass during antihypertensive treatment with either an $AT_{1}$ ‐receptor antagonists or a beta1 ‐adrenoceptor blocker. The polymorphism was hypothesized to have an impact mainly on the irbesartan group. Methods: We determined the association between the $TGF‐β_{1}$ genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double‐blind study to receive treatment for 48 weeks with either the $AT_{1}$ ‐receptor antagonist irbesartan or the beta1 ‐adrenoceptor blocker atenolol. Results: Irbesartan‐treated patients who were carriers of the C‐allele, which is associated with low expression of $TGF‐β_{1}$, responded with a markedly greater decrease in LV mass index (LVMI) than subjects with the G/G genotype (adjusted mean change in LVMI –44.7 $g/m^{2}$ vs. –22.2 $g/m^{2}$, p = 0.007), independent of blood pressure reduction. No association between genotype and change in LVMI was observed in the atenolol group. Conclusions: The TGF‐ $β_{1}$ G + 915C polymorphism is related to the change in LVMI in response to antihypertensive treatment with the $AT_{1}$ ‐receptor antagonist irbesartan. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6654118/pdf |
| Ending Page | 173 |
| Page Count | 5 |
| Starting Page | 169 |
| e-ISSN | 19328737 |
| DOI | 10.1002/clc.4960270315 |
| Journal | Clinical Cardiology |
| Issue Number | 3 |
| Volume Number | 27 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2004-03-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Clinical Cardiology Cardiology and Cardiovascular Diseases Transforming Growth Factor Left Ventricular Hypertrophy |
| Content Type | Text |
| Resource Type | Article |
